Select Publications
Bonner JA et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354(6):567-78. Abstract
Bonner JA et al. The relationship of cetuximab-induced rash and survival in patients with head and neck cancer treated with radiotherapy and cetuximab. Proc ASTRO 2005; No abstract available
Calais G et al. Randomized phase III trial comparing induction chemotherapy using cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000-01. Proc ASCO 2006; Abstract 5506
Cooper JS et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350(19):1937-44. Abstract
Forastiere AA et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil vs methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992;10(8):1245-51. Abstract
Jacobs C et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10(2):257-63. Abstract
Kim ES et al. Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer. Proc ASCO 2007; Abstract 6013
Lynch TJ Jr et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007;12(5):610-21. Abstract
Pfister DG et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006;24(7):1072-8. Abstract
Posner MR et al; TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357(17):1705-15. Abstract
Remenar E et al. A randomized phase III multicenter trial of neoadjuvant docetaxel plus cisplatin and 5-fluorouracil (TPF) versus neoadjuvant PF in patients with locally advanced unresectable squamous cell carcinoma of the head and neck (SCCHN). Final analysis of EORTC 24971 [TAX 323]. Proc ASCO 2006;Abstract 5516.
Salama JK et al. Chemoradiotherapy for locally advanced head and neck cancer. J Clin Oncol 2007;25(26):4118-26. No abstract available
Saltz L et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc ASCO 2003;Abstract 817.
Vermorken J et al. Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy — Results of a randomized phase III (Extreme) study. Proc ASCO 2007a;Abstract 6091.
Vermorken JB et al; EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007b;357(17):1695-704. Abstract
|
EDITOR
Neil Love, MD
INTERVIEWS
Edward S Kim, MD
- Select Publications
Marshall R Posner, MD
- Select Publications
 |
 |
 |
 |
